Table 1 The characteristics of the included studies in the meta-analysis
The first author | Investigated drug | Publication Date | Type of study | Study location | Types of diseases | Test | Number of the patients | Age (year) | Sex Female (%) | Prevalence of resistance (%) | Hypertension (%) | Hyperlipidemia (%) | Diabetes (%) | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sadeghi, M | Aspirin | 2012 | Retrospective study | Isfahan (center) | ischemic heart disease | Thromboxane B2 level in urine (ELISA) | 170 | 60.42 ± 8.43 | 79 (46.5) | 75.3% | 58.8% | 47.1% | 25.3% | 25 |
Kojuri, J | Aspirin | 2010 | Crossover | Shiraz (center) | percutaneous coronary angioplasty | light transmission aggregometry | 106 | 56.07 ± 10.13 | 66 (62.26) | 30.2% | 54.7% | 84.9% | 12.2% | 24 |
Eskandarian, R | Aspirin | 2012 | Cross-sectional | Semnan (north eastern) | coronary artery diseases | urinary 11-dehydro-thromboxane B. | 124 | 61.8 ± 9.7 | 50 (40.3) | 49.2% | 33.8% | NR | 28.2% | 23 |
Aghajania, HM | clopidogrel | 2018 | Cross-sectional | Tehran (center) | angioplasty | light transmission aggregometry (LTA) | 105 | 60.30 ± 12.2 | 64 (61%) | 24.76% | 65.71% | NR | 20.95% | 21 |
Aghajani, HM | clopidogrel | 2013 | Before-and-after | Tehran (center) | undergoing angioplasty | light transmission aggregometry (LTA) | 31 | 59 ± 13 | 12 (38.7) | 13% | 54.8% | NR | 19.4% | 22 |